FULC
Fulcrum Therapeutics, Inc.Company Information
- Company Name
- Fulcrum Therapeutics, Inc.
- CIK
- CIK0001680581
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- FULC: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- FULC
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-07-17
- Last sale
- 2026-06-26
- Shares purchased (TTM)
- 158,322
- Shares sold (TTM)
- 4,241,591
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 78,306,335
- Shares outstanding
- 76,264,000
- Ownership
- 102.68%
Earnings Market Reaction
- Filing date
- 2026-07-30
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 48 | 50 | 198 | 47 | 43 | 42 | 58 | 73 | 87 | 40 | 26 | 30 | ||||||
| Marketable Securities | 270 | 283 | 155 | 154 | 172 | 184 | 183 | 185 | 187 | 173 | 211 | 227 | ||||||
| Unbilled Receivables Current | - | - | 0 | 0 | 0 | 1 | 2 | 4 | 2 | 0 | 1 | 1 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 5 | 5 | 5 | 5 | 5 | 7 | 7 | 4 | 5 | 5 | 5 | ||||||
| Assets Current | 323 | 339 | 357 | 206 | 219 | 233 | 250 | 267 | 280 | 218 | 242 | 262 | ||||||
| Property Plant And Equipment Net | 0 | 2 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | ||||||
| Operating Lease Right Of Use Asset | 0 | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 8 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | ||||||
| Assets | 324 | 347 | 366 | 215 | 229 | 243 | 261 | 279 | 294 | 233 | 258 | 279 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 2 | 2 | 3 | 2 | 2 | 1 | 4 | 4 | 4 | 3 | 4 | ||||||
| Operating Lease Liability Current | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Deferred Revenue Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities Current | 10 | 10 | 13 | 12 | 9 | 8 | 11 | 15 | 13 | 11 | 14 | 14 | ||||||
| Operating Lease Liability Noncurrent | 3 | 3 | 4 | 5 | 5 | 6 | 6 | 7 | 8 | 8 | 9 | 9 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 13 | 13 | 17 | 16 | 14 | 14 | 18 | 22 | 20 | 19 | 23 | 23 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 951 | 947 | 943 | 772 | 769 | 765 | 762 | 760 | 755 | 751 | 745 | 741 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -639 | -613 | -594 | -574 | -554 | -537 | -519 | -503 | -481 | -537 | -510 | -485 | ||||||
| Stockholders Equity | 311 | 333 | 349 | 198 | 214 | 228 | 243 | 257 | 274 | 214 | 235 | 255 | ||||||
| Liabilities And Stockholders Equity | 324 | 347 | 366 | 215 | 229 | 243 | 261 | 279 | 294 | 233 | 258 | 279 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 76 | 67 | 67 | 54 | 54 | 54 | 54 | 54 | 62 | 62 | 62 | 62 | ||||||
| Shares Outstanding | 76 | 67 | 67 | 54 | 54 | 54 | 54 | 54 | 62 | 62 | 62 | 52 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialFulcrum Therapeutics, Inc. (FULC) — SEC Financial Statements & Analysis
Fulcrum Therapeutics, Inc. (FULC) is a pharmaceutical preparations company, incorporated in DE. Fulcrum Therapeutics, Inc. trades on Nasdaq as: FULC. Fulcrum Therapeutics, Inc. (FULC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, Fulcrum Therapeutics, Inc. carries a market cap of $279.13M, a P/E ratio of -3.28x, a P/B ratio of 0.90x, a P/S ratio of 2.25x, an enterprise value of $230.66M, and an EV/EBITDA multiple of -2.43x. On profitability, it posts an operating margin of -15.58%, a net margin of -0.64%, a Return on Equity (ROE) of -32.38%, a Return on Assets (ROA) of -30.75%, and a Return on Invested Capital (ROIC) of -44.26%. Per share, it reports EPS of $-1.11, diluted EPS of $-1.11, free cash flow per share of $-0.87, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 16.10% year-over-year, and EPS growth of -4.79% year-over-year. On the balance sheet, it maintains a current ratio of 31.35x, a quick ratio of 30.96x, working capital of $312.55M, a debt-to-equity ratio of 0.04x, a debt ratio of 0.04, an interest coverage ratio of -8.69x, free cash flow of $-66.14M (TTM), and net debt of $-48.47M. Figures sourced from SEC EDGAR.
- Market Cap
- $279.13M
- P/E TTM
- -3.28x
- EPS TTM
- $-1.11
- P/B TTM
- 0.90x
- ROE TTM
- -32.38%
- ROA TTM
- -30.75%
- Debt To Equity
- 0.04x
- Free Cash Flow TTM
- $-66.14M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Fulcrum Therapeutics, Inc. in?
Fulcrum Therapeutics, Inc. (FULC) operates in the Pharmaceutical Preparations industry.
What exchange does FULC trade on?
Fulcrum Therapeutics, Inc. (FULC) trades on the Nasdaq.
Where is Fulcrum Therapeutics, Inc. incorporated?
Fulcrum Therapeutics, Inc. is incorporated in DE.
When was Fulcrum Therapeutics, Inc. (FULC)'s most recent SEC filing?
Fulcrum Therapeutics, Inc. (FULC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30.
What is FULC's market cap?
Fulcrum Therapeutics, Inc. (FULC) has a market capitalization of $279.13M as of 2026-06-30.
What is FULC's EPS (earnings per share)?
Fulcrum Therapeutics, Inc. (FULC)'s trailing twelve month EPS is $-1.11 as of 2026-06-30.
What is FULC's ROE (return on equity)?
Fulcrum Therapeutics, Inc. (FULC)'s trailing twelve month Return on Equity (ROE) is -32.38% as of 2026-06-30.
What is FULC's ROA (return on assets)?
Fulcrum Therapeutics, Inc. (FULC)'s trailing twelve month Return on Assets (ROA) is -30.75% as of 2026-06-30.
What is FULC's ROIC (return on invested capital)?
Fulcrum Therapeutics, Inc. (FULC)'s trailing twelve month Return on Invested Capital (ROIC) is -44.26% as of 2026-06-30.
What is FULC's EV/EBITDA?
Fulcrum Therapeutics, Inc. (FULC)'s trailing twelve month EV/EBITDA is -2.43x as of 2026-06-30.